MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejpb.2025.114719

Медицинская библиотека · European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2025

A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats.

Niessen Janis, Arendt Nathalie, Sjöblom Markus, Dubbelboer Ilse R, Borchardt Thomas, Koziolek Mirko, Hedeland Mikael, Lennernäs Hans, Indulkar Anura, Dahlgren David

СтатьяПеревод в очереди

Аннотация

AIM: Proteolysis targeting chimeras (PROTACs) exhibit a unique and promising pharmacology. However, this comes with molecular properties exceeding the 'drug-like' rule of five chemical space, which often limits gastrointestinal absorption. This in vivo study aimed to investigate the contribution of luminal and plasma stability, intestinal effective permeability, P-glycoprotein (P-gp) efflux, and bile excretion, on the rat intestinal absorption and systemic exposure of two PROTACs, ARV-110 (812 Da, LogD7.4 4.8) and ARV-471 (724 Da, LogD7.4 4.6).

METHODS

Luminal stability and effective intestinal permeability were determined directly from luminal disappearance using single-pass intestinal perfusion, with and without a protease inhibitor, or a P-gp/Cytochrome P450 CYP3A inhibitor (ketoconazole) in rats. Plasma stability was tested by in vitro incubations. Intestinal absorption, systemic exposure, and biliary excretion were examined after intraduodenal and intravenous dosing with ketoconazole or the P-gp selective inhibitor (encequidar).

RESULTS AND DISCUSSION: Both PROTACs were degraded in the intestinal lumen and in plasma by peptidases. The intestinal effective permeability in rats was moderate for ARV-110 (0.62 × 10-4 cm/s) and low for ARV-471 (0.23 × 10-4 cm/s). P-gp inhibition increased the permeability 1.6- and 2.3-fold for ARV-110 and ARV-471, respectively. After intraduodenal dosing with the P-gp inhibitors a corresponding increase in systemic exposure was observed for both PROTACs. There was only a minor difference in the increased systemic exposure induced by the two inhibitors, suggesting that the mechanisms were primarily P-gp inhibition, rather than gut-wall and hepatic extraction. Biliary excretion was a minor pathway and did not affect the absorption and systemic exposure of the PROTACs to a large extent.

CONCLUSION

In the rat, ARV-110 and ARV-471 were enzymatically degraded in the intestinal lumen and in plasma, and their intestinal permeability and systemic exposure seem to be reduced due to P-gp efflux.

Для цитирования: Niessen Janis, Arendt Nathalie, Sjöblom Markus, Dubbelboer Ilse R, Borchardt Thomas, Koziolek Mirko, Hedeland Mikael, Lennernäs Hans, Indulkar Anura, Dahlgren David. A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats.. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2025. DOI: 10.1016/j.ejpb.2025.114719.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.